Abstract: The present invention relates to compositions comprising 2?-Fucosyllactose (2?-FL), for use in the reduction of nociception in an infant or in a young child by increasing Kynurenic acid production by the microbiota of an infant or a young child consuming the nutritional composition in the form of a growing up milk. The compositions are in particular useful in reducing abdominal pain, such as pain associated with infantile colic, irritable bowel syndrome (IBS) and/or recurrent abdominal pain (RAP), and consequently also contribute to reducing the crying periods and to improving the quality of sleep and the general quality of life of the infants and young children.

Abstract: Compositions contain 6?-sialyllactose (6? SL) and lacto-N-tetraose (LNT), for use in the reduction of nociception in an infant or in a young child. The compositions are in particular useful in reducing abdominal pain, such as pain associated with infantile colic, irritable bowel syndrome (IBS) and/or recurrent abdominal pain (RAP), and consequently also contribute to reducing the crying periods and to improving the quality of sleep and the general quality of life of the infants and young children.

Abstract: The present invention relates to nutritional compositions comprising 6?-sialyllactose (6?SL) and lacto-N-tetraose (LNT) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gut barrier function in an infant, a young child or children aged above 3 years to 8 years.

Abstract: A method for reducing nociceptive sensitivity in non-infant humans includes in some examples selecting a non-infant human experiencing a condition and associated nociceptive sensitivity (e.g., irritable bowel syndrome or chronic neuropathic pain). In such examples, the method further includes selecting an effective amount of one or more human milk oligosaccharides (“HMOs”) chosen from the group consisting of 6?-sialyllactose (6?-SL), and a mixture of 6?-SL and lacto-N-tetraose (LNT) and reducing the nociceptive sensitivity by administering the selected effective amount of the chosen HMOs to the non-infant human during an initial phase. In some examples, the method includes activating GPR35 receptors by administering the effective amount of the chosen one or more HMOs. In some examples, the HMOs are a mixture of 6?-SL and LNT that provides a synergistic effect relative to each of the 6?-SL and LNT alone.

Abstract: The present invention relates to compositions comprising 6?-sialyllactose (6?SL) and lacto-N-tetraose (LNT), for use in the reduction of nociception in an infant or in a young child. The compositions are in particular useful in reducing abdominal pain, such as pain associated with infantile colic, irritable bowel syndrome (IBS) and/or recurrent abdominal pain (RAP), and consequently also contribute to reducing the crying periods and to improving the quality of sleep and the general quality of life of the infants and young children.

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human. The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).

Abstract: The present invention relates to nutritional compositions comprising 2?-Fucosyllactose (2?FL) for use in improving the gastrointestinal barrier. In particular, the present invention relates to improving gastrointestinal barrier in an infant, a young child or children aged above 3 years to 8 years.

Abstract: A composition and associated packs and methods for (i) promoting gastrointestinal barrier healing in the upper intestinal tract and/or small intestine of a non-infant human suffering from chronic intestinal barrier inflammation, and/or (ii) maintaining remission in the upper intestinal tract and small intestine of a non-infant human suffering from chronic intestinal barrier inflammation. The composition contains an effective amount of a combination of 6?-sialyllactose (6?-SL) and lacto-N-tetraose (LNT).

Abstract: The present invention relates to a nutritional composition comprising at least one human milk oligosaccharide for use in preventing and/or treating a health disorder in an infant or young child by increasing GLP-1 in said infant or young child.

Abstract: The present invention relates to a nutritional composition comprising at least one sialylated oligosaccharide, for use in reducing and/or avoiding excessive fat mass accumulation, in preventing the associated later in life health disorders like later in life obesity and related comorbidities, in reducing and/or controlling food intake and/or in promoting a healthy growth in an infant or a young child.

Abstract: The application relates to synthetic compositions and methods for preventing or reducing nociception and/or nociceptive sensitivity in a non-infant human The human is administered a composition comprising 6?-sialyllactose (6?-SL) and/or lacto-N-tetraose (LNT).

Abstract: The present invention relates to compositions comprising 6?-sialyllactose (6?SL) and lacto-N-tetraose (LNT), for use in the reduction of nociception in an infant or in a young child. The compositions are in particular useful in reducing abdominal pain, such as pain associated with infantile colic, irritable bowel syndrome (IBS) and/or recurrent abdominal pain (RAP), and consequently also contribute to reducing the crying periods and to improving the quality of sleep and the general quality of life of the infants and young children.

Abstract: The present invention relates to the field of weight management and the prevention and/or treatment of metabolic disorders. In particular, the present invention provides a composition comprising at least one Trpm5 inhibitor which is effective in the treatment of prevention of metabolic disorders or risk factors thereof, such as overweightness or obesity, without having to reduce food intake below metabolic needs.

Abstract: The present invention relates to the field of nutritional compositions. In particular, the present invention relates to a nutritional composition comprising sugar substitutes and to their use, e.g., to increase exogenous carbohydrate oxidation, which has been shown to increase performance, for example the performance of athletes.

Abstract: The present invention relates in general to field of food and drinks. In particular, in relates to formulations that mimic the taste of fat but that are lower in calories. One embodiment of the present invention relates to the use of at least one non-fat agonist of GPR40 for imparting a fatty taste to a food product.

Abstract: The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses transgenic animals and cells that do not express functional T1R3 protein, particularly knock-out animals and cells, and transgenic animals and cells that express a non-native T1R3 protein. Experimental model systems based on these animals and cells can be used to study T1R3-mediated taste transduction and responses of the components of the T1R3 signal transduction pathway to various tastants, furthering our understanding of the molecular biology and biochemistry of taste. Such model systems would also be useful for screening for novel tastants and taste modulators, such as enhancers of desirable flavors, and blockers of undesirable flavors.

Abstract: Fat taste receptors and methods for using the receptors to screen compounds that mimic fat taste are disclosed. The receptors can include G-protein coupled receptor proteins, such as GPR40 or GPR120. New methods for preparing foods are also disclosed that involve testing compounds in the assay system and then incorporating into foods the identified nonfat compounds that have the taste of fat.

Abstract: The present invention relates to the discovery, identification and characterization of a receptor protein, referred to herein as T1R3, which is expressed in taste receptor cells and associated with the perception of bitter and sweet taste. The invention encompasses transgenic animals and cells that do not express functional T1R3 protein, particularly knock-out animals and cells, and transgenic animals and cells that express a non-native T1R3 protein. Experimental model systems based on these animals and cells can be used to study T1R3-mediated taste transduction and responses of the components of the T1R3 signal transduction pathway to various tastants, furthering our understanding of the molecular biology and biochemistry of taste. Such model systems would also be useful for screening for novel tastants and taste modulators, such as enhancers of desirable flavors, and blockers of undesirable flavors.